Phreesia (NYSE:PHR – Get Free Report) and Evolent Health (NYSE:EVH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.
Insider and Institutional Ownership
92.1% of Phreesia shares are held by institutional investors. 5.2% of Phreesia shares are held by company insiders. Comparatively, 1.5% of Evolent Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Phreesia has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Evolent Health has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.
Profitability
This table compares Phreesia and Evolent Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Phreesia | 2.06% | 5.22% | 3.02% |
| Evolent Health | -21.67% | -6.07% | -1.23% |
Earnings & Valuation
This table compares Phreesia and Evolent Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Phreesia | $480.59 million | 1.64 | $2.31 million | $0.17 | 74.74 |
| Evolent Health | $1.88 billion | 0.29 | -$534.51 million | ($4.54) | -1.08 |
Phreesia has higher earnings, but lower revenue than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Phreesia and Evolent Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Phreesia | 2 | 9 | 8 | 0 | 2.32 |
| Evolent Health | 1 | 3 | 10 | 0 | 2.64 |
Phreesia currently has a consensus target price of $13.87, indicating a potential upside of 9.14%. Evolent Health has a consensus target price of $6.04, indicating a potential upside of 23.61%. Given Evolent Health’s stronger consensus rating and higher probable upside, analysts plainly believe Evolent Health is more favorable than Phreesia.
Summary
Phreesia beats Evolent Health on 9 of the 14 factors compared between the two stocks.
About Phreesia
Phreesia, Inc. provides software and services that help healthcare organizations manage interactions with patients. Its platform supports tasks such as patient registration and intake, appointment scheduling, payments, and communications before and after visits. Phreesia’s tools include digital and mobile options for completing forms and sharing information, as well as services designed to help providers engage patients and streamline administrative workflows. The company serves healthcare providers and organizations primarily in the United States.
About Evolent Health
Evolent Health, Inc. provides technology-enabled services to health plans and healthcare providers in the United States. The company helps clients manage care, coordinate services and support the delivery of healthcare, particularly for people with complex medical needs. Its offerings include specialty care management programs, clinical and administrative services, and technology that supports care decisions and operations. Evolent has focused on areas such as oncology, cardiology, musculoskeletal care and behavioral health.
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
